

# Notice of CIG Media Group's Compliance with the NIH Public Access Policy

Authors may request the final, edited manuscript from CIG to send to the PubMed Central archive as instructed by the NIH Public Access Policy (NOT-OD-08-033); The embargo period for the published article to be made available for public access by PubMed Central is 12 months after the date of print publication.

CIG reserves the right to change or rescind this policy. CIG's copyright transfer agreements are compliant with the NIH Public Access Policy and are not superseded or altered by the NIH's policy.

For any questions regarding CIG's policy or our submission process, please contact the Editorial Office at 214-367-3359 or [manuscript@cigjournals.com](mailto:manuscript@cigjournals.com).

For more information on the NIH Public Access Policy, please go to <http://publicaccess.nih.gov>.

## About CIG Media Group, LP

Dallas-based CIG Media Group, LP, is a subsidiary of Medical Media Holdings, LLC. Founded in 1996, CIG Media Group, LP, is the premier publisher of seven peer-reviewed, tumor-specific medical oncology journals: *Clinical Lung Cancer*, *Clinical Colorectal Cancer*, *Clinical Breast Cancer*, *Clinical Lymphoma & Myeloma*, *Clinical Leukemia*, *Clinical Genitourinary Cancer*, and *Clinical Ovarian Cancer*. All of the company's established journals are indexed in PubMed. Each year, CIG Media Group, LP, also publishes multiple tumor-specific journal supplements that provide oncology professionals with opportunities to earn American Medical Association-accredited continuing medical education credits. For more information about CIG Media Group, LP, and our clinical oncology journals, please visit [www.cigjournals.com](http://www.cigjournals.com).



ANNOUNCEMENT